Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor therapy in patients with renal cell carcinoma who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib-Results of NCI/CTEP protocol 9048

Thomas J. Semrad, Susan Groshen, Chunqiao Luo, Sumanta Pal, Ulka Vaishampayan, Monika Joshi, David I. Quinn, Philip C. MacK, David R. Gandara, Primo N. Lara

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor therapy in patients with renal cell carcinoma who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib-Results of NCI/CTEP protocol 9048'. Together they form a unique fingerprint.

Medicine & Life Sciences